An open-label, randomized, 3-way crossover study to evaluate the relative bioavailability of a single oral dose of naproxen 500 mg administered as PN 400 (naproxen / esomeprazole), as the [active comparator 1], or as [active comparator 2] in healthy volunteers

Trial Profile

An open-label, randomized, 3-way crossover study to evaluate the relative bioavailability of a single oral dose of naproxen 500 mg administered as PN 400 (naproxen / esomeprazole), as the [active comparator 1], or as [active comparator 2] in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2010

At a glance

  • Drugs Esomeprazole/naproxen; Naproxen
  • Indications Arthritis; Musculoskeletal pain; NSAID-induced gastrointestinal damage
  • Focus Pharmacokinetics
  • Sponsors POZEN
  • Most Recent Events

    • 09 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top